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ABSTRACT 
 
Majority of the drugs are taken by the oral route but it is not effective. To improve the effectiveness  a route 
emerged known as Transdermal route. This give rise to Transdermal drug delivery system. Transdermal drug 
delivery systems (TDDS) are dosage forms that involves drug transport to viable epidermal or dermal tissues of the 
skin for therapeutic effect while a major fraction of drug is transported into the systemic blood circulation. 
Transdermal drug delivery can be improved by the use of involves the use of penetration enhancers which penetrate 
into skin to reversibly reduce the barrier resistance. Transdermal delivery have various advantages such as 
avoidance of presystemic and systemic first pass metabolism ,controlled release, provides non-invasive and easily 
terminable means for systemic as well as topical drug delivery. This article provides an overview of TDDS, its 
advantages over conventional dosage forms, drug delivery routes across skin, penetration enhancers, various 
components of Transdermal patches, types of Transdermal patches, methods of preparation, methods of evaluation, 
marketed preparations.  
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Introduction 
 
Transdermal drug delivery system are the dosage forms 
that is applied to the body surface and is designed to 
deliver the therapeutic  effective amount of drug across 
the skin, into the systemic circulation.[1]Currently, 
transdermal drug delivery is one of the most prominent 
way for drug delivery to the systemic circulation via 
skin.[2] conventional methods of drug administration 
are effective for most of the drugs but some drugs are 
unstable,toxic and have narrow therapeutic ranges. 
Oral drug delivery is by far the most convenient mode 
of delivering drugs especially when repeated or routine 
administration is required. As the two faces of a coin 
TDDS has advantage of easy administration, but has 
significant drawbacks also such as poor bioavailability 
due to hepatic metabolism  and the tendency to produce  
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rapid blood level spikes, leading to a need for  frequent 
dosing, which is inconvenient.[3]Controlled delivery of 
drugs through human skin has been the field of 
research for investigators and transdermal devices have 
been developed for drugs such as clonidine,estradiol, 
testosterone,fentanyl,scopolamine,nitroglycerin,estrogen 
etc.[4] 
 
Advantages of TDDS 
• Avoidance of first pass metabolism thus 
increasing bioavailability and efficacy of 
drugs. 
• Suitable for unconscious patients,thus act as a 
substitute to oral drug delivery(in case of 
vomiting). 
• Avoidance of gastro intestinal incompatibility. 
• Non invasive in nature thus avoid the risk and 
inconvenience of intravenous administration 
of drugs.  
• Maintain plasma concentration of potent 
drugs. 
• Dose reduction. 
• Reduced inter and intra patient variations. 
• Therapy can be terminated at any point of 
time just by removing the patch. 
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• Greater patient compliance due to elimination 
of multiple dosing profiles. 
• No fluctuations of drug levels in plasma and 
blood. 
• Predictable and extended duration of activity. 
• Improved physiological and pharmacological 
response. 
• No effect of food intake. 
• Extended therapy avoiding frequent dose 
administration.[5,6] 
Disadvantages of TDDS 
 
• Potent drugs are the suitable candidates as 
certain drugs are skin impermeable. 
• Skin irritation and inflammation occurs 
sometimes due to application of patches. 
• System components may cause dermatitis at 
the site of application thus discontinuation 
becomes necessary 
• It cannot be used for molecules of size greater 
than 500 Daltons. 
• The bacteria acting as a host on skin break 
certain drugs before penetration of it through 
stratum corneum. 
• Achievement of high drug levels in plasma 
cannot be attained. 
• Metabolic enzymes present in the skin 
metabolises some of the drugs before 
penetration through its layers. 
• Significant lag time cannot be attained 
• Tolerance inducing drugs or hormones 
requiring chronopharmacological management 
is not suitable candidates for TDDS. 
• Use of TDDS is uneconomic. [7, 8] 
 
  
Carrier based TDDS 
Carrier 
 
 
 
                     LIPID BASED                               POLYMER BASED               SURFACTANT BASED 
1. Vesicle based                              1.Biodegradable particles         1.Vesicle based 
                                  Liposomes                                2.Non Biodegradable                Micelles 
                                  Ethosomes                                3.Dendrimers                            Niosomes 
  2. Particle based                                                                                2.Emulsion based 
         SLNs                                                                                                  Microemulsions 
         SLMs                                                                                                  Nanoemulsions 
                                NLCs 
Drug delivery routes across the human skin 
Drug molecules can enter the skin by three major 
pathways. 
• Through sweat glands with the help of hair 
follicles 
• Through sebaceous glands 
• Through stratum corneum 
Skin has excellent barrier property, this is the utmost 
problem associated with dermal delivery system. 
[9].Figure 1 represents the pathways for delivery of 
drugs across the skin. 
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Fig 1: Representation of permeation of drugs through sweat 
sebaceous glands 
 
Penetration enhancers 
Table 1 shows the penetration enhancers for T
Class Representative compounds
Water - 
Alcohols Ethyl alcohol
C2H5
Polyols: polyethylene glycol 
HOCH2 
Pyrrolidones N-methyl  2
        
Azone® 1-Dodecylhexa
3-25                                        
, 2014; 1(1): 13-25
   
glands(via hair follicles),
ransdermal drug delivery system
 Mechanism of action
Increase the solubility of the 
permeate[10]
 
OH 
Co-permeates with the drug 
through the lipid 
channels,partial extraction of 
lipids[11]
 
- (CH2 - O - CH2)n - CH2OH. 
Replaces bound water in the 
intercellular space, enhances 
penetration of lipophilic 
drugs.[12]
-pyrrolidone 
 
Increases the diffusivity, and 
reduces passage through the 
non polar route by decreasing 
diffusivity and 
partitioning.Interacts with both 
the keratin and lipid 
component o
corneum. [13,14]
-hydro-2H-azepine-2-one Disruption of skin 
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 stratum corneum, 
 
 
 
 
 
f the Stratum 
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Fatty acids and esters Oleic acid, lauric acid, linolic acid,
myristic acid,cetyl oleate
                     
                      
Surfactants 
 
 
 
Polysorbates (Tweens)Polyoxyethylene 
alkylphenols,Dodecyltrimethyl ammonium 
bromide,Sodium lauryl sulfate
Bile salts sodium choleate, an ox bile extract containing the 
sodium salts of taurocholic, glycoeolic,
desoxycholic and cholic acids, and of the free 
choleic acids
Essential 
oils,terpenes,terpenoids 
Limonene
d-limonene; menthone; nerodidol; carvone;
carvacrol; linalool; pulegone; 
                 
         
Phospholoipids Phosphatidylcholine from
soybean or egg yolk
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lipids[15,16,17]
 
 
 
Cetyl oleate 
Oleic acid 
Increases the fluidity of 
intercellular lipids[18,19]
 
 
Penetrates into skin, causing 
micellar solubi
Stratum corneum lipids.
Extract lipid from stratum 
corneum. [20]
 
 
 
enhance the
penetration of progesterone 
and prednisolone[21]
 Ascaridole; 1,8-cineole; l-menthol; 
 
α-pinene 
 
         Limonene 
Modify the solvent nature of 
stratum corneum,thus 
improving drug partition into 
tissues.[22]
 
 
 
Diffuses into Stratum 
corneum, disorders 
intercellular lipids,Enhances 
drug 
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lization of 
 
 
 transcutaneous 
 
 
partitioning into skin[23] 
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Components of TDDS 
Table 2: Shows components and their characteristics 
Components Characteristics 
Polymer matrix/Drug reservoir Mechanism of drug release depends on the physicochemical properties of 
drug and polymer 
Classification of polymers used in TDDS is as follows: 
1. Natural polymers: e.g. cellulose derivatives, zein, 
gelatin, shellac, waxes, gums, natural rubber andchitosan etc. 
2.Synthetic elastomers: e.g. polybutadiene,polyisobutylene, silicon rubber, 
nitrile, acrylonitrile,neoprene, butylrubber etc. 
3.Synthetic polymers: e.g. polyvinyl alcohol,polyvinylchloride, polyethylene, 
polypropylene,polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, 
polymethylmethacrylate etc.[24] 
Drug The ideal characteristics of drug are as follows: 
 
1.should have some degree of solubility of lipophilic and hydrophilic 
character (ideally greater than 1 mg/ml)  
2.should have melting point less than 200 °C.  
3.should have molecular weight of less than 1000 units.  
4. Saturated aqueous solution of the drug should have a pH value between 5 
and 9.  
5. Hydrogen bonding groups should be less than 2.  
6. should have short biological half life  
7. should be non irritant  to human skin  
8.Tolerance to drug must not develop under near zero order release profile of 
transdermal delivery  
9. should not get irreversibly bound in the subcutaneous tissue  
10.The should not get extensively metabolized in the skin [25] 
Permeation enhancers 1. interacting with structural components of stratum corneum i.e., proteins or 
lipids to attain higher therapeutic levels of the drug  and increase the 
permeability 
2.chemically modify the barrier functions leading to increased permeability of 
stratum corneum[26-27] 
Adhesive layers 1.must be skin-compatible 
 2.must be able to dissolve drug and Excipient in quantities sufficient for the 
desired  effect(pharmacological) 
Three major classes of adhesives used are as follows: 
Polyisobutylene type pressure sensitive adhesives  
Acrylic type pressure sensitive adhesives  
Silicone type pressure sensitive adhesives  
Release liners 1. Prevents the loss of the drug that has migrated into the adhesive layer 
during storage. 
 2. Prevents contamination.  
3.It is composed of a base layer, which may be nonocclusive or occlusive, and 
a release coating layer made of silicone,teflon 
Backing laminates 1. Provide support.  
2. Prevent drug from leaving the dosage form through top.  
3. Must be impermeable to drugs and permeation enhancers.  
4. Should have low moisture vapor transmission rate.  
5. Must have optimal elasticity, flexibility, and tensile strength.  
6. Must be chemically compatible with the drug, enhancer, adhesive and other 
excipients. 
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Rate controlling membrane 
                                    
 
Types of transdermal drug delivery system
Table 3: Shows r
Type Characteristics
Single layer Drug in adhesive 1.Adhesive layer contains the 
drug,adhere the various layers 
together and also responsible 
for the releasing the drug to the 
skin. 
2.The adhesive layer is 
surrounded by a temporary
liner and a backing.
Multi layer Drug in adhesive 1.It is composed of a immediate 
drug release layer and other 
layer will be a controlled 
release along with the adhesive 
layer. 
2.This patch also has a 
temporary liner
permanent backing.
Matrix It is of two types:
1.Drug in adhesive system
2.Matrix dispersion system
Reservoir 1.Drug reservoir is embedded 
between an
impervious backing layer and a 
rate controlling
membrane. 
2.The drug releases only 
through the rate controlling
membrane, 
porous or non
3-25                                        
, 2014; 1(1): 13-25
   
7. Must be relatively inexpensive and must allow printing and adhesive 
lamination.  
Made of polymeric material such as chitosan,
methacrylate (PHEMA)  
 
epresentation, characteristics and types of TDDS
 Representation 
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porous.
Vapour patch 1.Adhesive layer adheres 
various layers together and act 
as release vapour
2.These patches help to improve 
sleep conditions and cessate 
smoking
Microreservoir system 1. The drug reservoir is form
by first suspending the drug in 
an aqueous solution of water 
soluble polymer and then 
dispersing the solution 
homogeneously in a lipophilic 
polymer to form, spheres of 
drug reservoirs.
2. It is stabilized quickly by 
cross
situ.[28
   
Methods of preparation 
Table 4: Shows v
Methods 
Assymetric  TPX membrane 
method 
Circular teflon mould method 
3-25                                        
, 2014; 1(1): 13-25
   
 
 
 
 
ed 
 
-linking the polymer in 
-32] 
arious methods of preparation of TDDS  
Description 
(1) Backing membrane-It is heat sealable polyester film with concave diameter of 
1 cm. 
(2) Drug sample is dispensed into the concave membrane
(3) Concave membrane is covered by TPX{poly(4
by an adhesive.  
[(Asymmetric TPX membrane preparation): 
(1)TPX is dissolved in a mixture of solvent (cyclohexane) an
additives at 60°C to form a polymer solution.  
(2)The polymer solution is kept at 40°C for 24 hrs and casted on a glass plat
pre-determined thickness.  
(3)The casting film is evaporated at 50°C for 30 sec. and then
be immersed immediately in coagulation bath [25°C]. 
(4)After 10 minutes of immersion, the membrane can be removed, air dry in a  
oven at 50°C for 12 hours.[33] 
Solutions containing polymers in various ratios are used in an organic solvent.
(1) Calculated amount of drug is dissolved in half the quantity of same organic 
solvent.  
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-methyl-1-pentene)} and sealed 
Dry/wet inversion process –
d nonsolvent 
e to a 
 the glass plate is to 
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2) Enhancers in different concentrations are dissolved in the other half of the 
organic solvent and then added.  
3) Di-N-butylphthalate is added as a plasticizer into drug polymer solution. 
4) The total contents are to be stirred for 12 hrs and then poured into a circular 
teflon mould.  
5) The moulds are to be placed on a leveled surface and covered with inverted 
funnel to control solvent vaporization in a laminar flow hood model with an air 
speed of 0.5 m/s.  
6) The solvent is allowed to evaporate for 24 hrs.  
7) The dried films are to be stored for another 24 hrs at 25±0.5°C in a desiccators 
containing silica gel before evaluation to eliminate aging effects. 
8) The films are to be evaluated within one week of their preparation.[34] 
Mercury substrate method 
 
1) Drug is dissolved in polymer solution along with plasticizer.  
2) The above solution is to produce a homogenous dispersion and poured in to a 
leveled mercury surface, covered with inverted funnel to control solvent 
evaporation.[35] 
Isopropyl myristate membrane  
method 
1) Drug is dispersed in a mixture of water and propylene glycol containing 
carbomer 940 polymer and stirred for 12 hrs in magnetic stirrer. 
2)The dispersion’s viscosity is increased  by the addition of triethanolamine.  
3)The formed gel is  incorporated in the IPM membrane.[36] 
Ethylenevinylacetate copolymer 
(EVAC) membranes method 
1)Drug is dissolved in propylene glycol, carbopol resin will be added to the 
solution (1% carbopol reservoir gel, polyethelene (PE), ethylene vinyl acetate 
copolymer (EVAC)) and neutralized by using 5% w/w sodium hydroxide 
solution.  
2)The drug (in gel form) is placed on a sheet of backing layer covering the 
specified area.  
3)EVACmembrane is  placed over the gel and the edges are sealed by heat to 
obtain a leak proof device.[37] 
Free film method 
 
1)Free film of cellulose acetate is prepared by casting on mercury surface.  
2)A polymer solution 2% w/w is prepared by chloroform. Plasticizers are 
incorporated at a concentration of 40% w/w of polymer weight.  
3)Five ml of polymer solution are poured in a glass ring which is placed over the 
mercury surface in a glass petri dish.  
4)The film formation is noted by observing the mercury surface after complete 
evaporation of the solvent.  
5)The dry film will be separated out and stored between the sheets of wax paper 
in a desiccator until use[38] 
Aluminium backed adhesive film 
method 
 
1)It is a suitable method in case where loading dose is greater than 10 mg. 
2)Chloroform is a  solvent of choice 
3) The drug is dissolved in chloroform and adhesive material is added to the drug 
solution and dissolved.  
4)A custom-made aluminium former is lined with aluminium foil and the ends 
blanked off with tightly fitting cork blocks.[39] 
Proliposomes method 1)The proliposomes are prepared by taking 5mg of mannitol powder in a round 
bottom flask (60-70°C) and the flask is rotated at 80-90 rpm and  mannitol  is 
dried  at vacuum for 30 minutes.  
2)Temperature of the water bath is adjusted to 20-30°C.  
3)Drug and lecithin (0.1:2.0) are dissolved in a suitable organic solvent mixture; a 
0.5ml aliquot of the organic solution is introduced into the RBF at 37°C, after 
complete drying second aliquot (0.5ml) of the solution is added.  
4)After the last loading, the flask containing proliposomes are connected to a 
lyophilizer and subsequently drug loaded mannitol powders (proliposomes) are 
placed in a desiccator over night and then sieved through 100 mesh.  
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5)The collected powder is put into a glass bottle and stored at the freeze 
temperature.[40] 
                                   
Evaluation of TDDS 
1. Interaction studies: (1) The stability of a 
formulation  depends on the compatibility of 
drug with excipients.  
(2) Interaction studies are commonly carried 
out by Thermal analysis, FT-IR, UV and 
chromatographic techniques. [41] 
2. Thickness of the patch:The thickness of the 
drug loaded patch is measured  by using a digital 
micrometer [42] 
3. Weight uniformity: A specified area of 
patch(predried at 60°C) is  cut in different parts 
of the patch and weighed. The average weight 
and standard deviation values are calculated 
from the individual weights.[43] 
4. Folding endurance: (1) A strip(specific area) is  
cut evenly and repeatedly folded at the same 
place till it broke.  
(2)The number of times the film could be folded 
at the same place without breaking is the value 
of the folding endurance.[44] 
5. Percentage Moisture content: (1)The prepared 
films are weighed individually and kept in a 
desiccators( containing fused calcium chloride) 
for 24 hrs. The films are reweighed and 
percentage moisture content is determined.[45] 
Percentage moisture content = [Initial weight- 
Finalweight/ Final weight] ×100 
6. Percentage Moisture uptake:1.The weighed 
films are  kept in a desiccator  for 24 hrs 
(containing saturated solution of KCl) in order 
to maintain 84% RH. The films are  reweighed 
and percentage moisture uptake is 
determined.[46] Percentage moisture uptake = 
[Final weight- Initialweight/ initial weight] ×100 
7. Water vapour permeability (WVP) 
evaluation:(1)Water vapour permeability  is 
determined with foam dressing method. 
(2).Natural air circulation oven is used.[47] The 
WVP can be determined    as: WVP=W/A 
Where, WVP is expressed in gm/m2 per 24hrs, 
W is the amount of vapour permeated through 
the patch expressed in gm/24hrs  A is the 
surface area of the exposure samples expressed 
in m2. 
8. Drug content:A specified area of patch is  
dissolved in a suitable solvent . Solution is  
filtered through a filter medium and drug 
content is analysed. [48] 
9. Polariscope examination:. Drug crystals 
examined by polariscope and A specific surface 
area of the piece is  kept on the slide and 
observe for the drugs crystals to distinguish 
whether the drug is present as crystalline form or 
amorphous form in the patch.[49] 
10. Shear Adhesion test: Cohesive strength of an 
adhesive polymer is determined and An 
adhesive coated tape is applied onto a stainless 
steel plate; a specified weight is hung from the 
tape. Shear adhesion strength is determined by 
measuring the time it takes to pull the tape off 
the plate. The longer the time take for removal, 
greater is the shear strength.[50] 
11. Peel Adhesion test: A single tape is applied to a 
stainless steel plate and then tape is pulled from 
the substrate at a 180º angle and The force 
required for tape removed is measured.(PEEL 
ADHESION FORCE)[51] 
12. Thumb tack test: The thumb is pressed on the 
adhesive & Relative tack property is 
detected.[52] 
13. Flatness test:Three longitudinal strips are  cut 
from each film at different portions ( one from 
the center, other one from the left side, and 
another one from the right side.) and The length 
of each strip was measured and the variation in 
length because of non-uniformity in flatness was 
measured by determining percent constriction, 
with 0% constriction equivalent to 100% 
flatness.[53] 
14. Percentage Elongation break test:1.It is 
determined by noting the length just before the 
break point.The percentage elongation can be 
determined as:. Elongation percentage = L1-L2 
×100 Where, L1is the final length of each strip 
and L2 is the initial length of each strip.[54] 
15. Rolling ball tack test: Softness of a polymer is 
measured. & Stainless steel ball is released on 
an inclined track so that it rolls down and comes 
into contact with horizontal, upward facing 
adhesive. The distance the ball travels along the 
adhesive provides the measurement of tack, 
which is expressed in inch.[55] 
16. Quick Stick (peel-tack) test:Tape is pulled 
away from the substrate at 90ºC at a speed of 12 
inches/min. The peel force required to break the 
bond between adhesive and substrate is 
measured and recorded as tack value.[56] 
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17. Probe Tack test:Probe(tip) with a  surface 
roughness is brought into contact with adhesive, 
A bond is formed between probe and 
adhesive.The subsequent removal of the probe 
mechanically breaks it. The force required to 
pull the probe away from the adhesive at fixed 
rate is recorded as tack.[57] 
18. In vitro drug release studies:The paddle over 
disc method (USP apparatus V) is used for 
assessment of the release of the drug from the 
prepared patches. Dry films is cut into definite 
shape, weighed, and fixed over a glass plate with 
an adhesive. The glass plate is then placed in a 
500-ml of the phosphate buffer (pH 7.4), and the 
apparatus is equilibrated to 32± 0.5°C.The 
paddle is set at a distance of 2.5 cm from the 
glass plate and operated at a speed of 50 rpm. 
Samples (5-ml aliquots) can be withdrawn at 
appropriate time intervals up to 24 h and 
analyzed by UV spectrophotometer.[58] 
19.  In vitro skin permeation studies: Diffusion 
cell is used for the study.Hair from the 
abdominal region(Wistar rats weighing 200 to 
250g) are  removed by a clipper; the dermal side 
of the skin is cleaned with water to remove any 
adhering tissues, equilibration is done for an 
hour in dissolution medium  before starting the 
experiment and is  placed on a magnetic stirrer 
with a small magnetic needle for uniform 
distribution of the diffusant.The temperature of 
the cell is maintained at 32 ± 0.5°C.The isolated 
rat skin piece is mounted between the 
compartments of the diffusion cell, with the 
epidermis facing upward into the donor 
compartment. Sample volume of definite 
volume is to be removed from the receptor 
compartment at regular intervals, and an equal 
volume of fresh medium is to be replaced. 
Samples can be analyzed 
spectrophotometrically. [59] 
Marketed preparations 
Table 5: Shows the market preparations of TDDS 
Drug Application Marketed Preparation 
Lidocaine For neuropathic pain relief[60] Lipoderm® 
Apomorphine HCl For parkinson’s disease[61] Passport TM Apomorphine patch 
Fentanyl For management of persistent, 
moderate to severe chronic pain 
that:  
1.Requires continuous, round-the-
clock opioid administration for an 
extended period of time 
2.Cannot be managed by other 
means such as nonsteroidal 
analgesics, opioid combinations, or 
immediate-release opioids [62] 
DURAGESIC® 
Nicotine help people stop smoking 
cigarettes[63] 
Nicoderm®CQPatch,Nicotrol® 
PatchProstep , Habitrao 
 
Nitroglycerine For angina pectoris[64] Deponit,Minitran,Nitrodisc, 
Nitrodur,TransdermNitro  
 
Clonidine For hypertension Catapres-TTS 
Estradiol For postmenstrual syndrome Climara ,Vivelle, Estraderm, 
Esclim,Alora 
Ethinyl Estradiol For postmenstrual syndrome Ortho Evra 
Testosterone For hypogonadism in males Androderm 
Nor ethindrone For hormone replacement therapy Combipatch 
Diclofenac epolamine Treatment of pain and 
inflammation 
Flector 
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Buprenorphine As analgesic for chronic pain Bu Trans 
Iselegiline For depression Emsam 
Rigotine For early-stage 
idiopathic 
Parkinson’s disease 
Neupro® 
Diclofenac 
diethylamine 
Antiinflammatory Nupatch 
Nitroglycerin estradiol For angina pectoris Minitran Climaderm 
Oxybutynin For bladder disorder Oxytrol® 
Estrogen For hormone replacement therapy Nuvelle TS 
Scopolamine For motion sickness Transderm Scop® 
 
For hypertension patches have been made for the 
following drugs: Timolol maleate, Nicardipine 
hydrochloride,Indapamide, Pinacidil, Verapamil 
hydrochloride. 
 
Conclusion 
This article reveals prominent knowledge regarding the 
transdermal drug delivery systems and its evaluation 
parmeters. These review work conclude that, older 
drugs by formulating them in new dosage forms has 
generated enthusiasm among the pharmaceutical 
scientists to develop new dosage forms TDDS have 
great potentials, being able to use for both hydrophobic 
and hydrophilic active substance into promising 
deliverable drugs. In addition, new dosage forms are 
essential for other drugs in order to enhance their 
performance by reducing their dose, increasing 
absorption, delivering to the target site etc.  
 
References 
1. M. R. Prausnitz, S. Mitragotri, R. Langer. Current 
status and future potential of transdermal drug 
delivery. Nature Reviews, Drug Discovery, 2004, 
3: 115-124. 
2. Kanikannan N, Andega S, Burton S, Babu RJ and 
Singh M F. Formulation and in vitro evaluation 
of  transdermal patches of melatonin, Drug 
Dev.Ind. Pharm, 2004;30:205-212. 
3. Williams AC and Barry BW. Penetration 
enhancers, Adv. Drug. Del. Rev.2004;56:603-618. 
4. Stamatialis DF, Bernke JP, Miriam G, Saiful S, 
Srivatsa NM, Stephanie S, Matthias W. Medical 
applications of membranes: Drug delivery, 
artificial organs and tissue engineering. J Membr 
Sci. 2008; 308: 1–34. 
5.  Mojtaba S. Transdermal excipients effect on 
adhesion strength of a pressure sensitive 
adhesive. Iranian Polymer Journal. 2003; 12 (3): 
243-248. 
6. Finnin BC, Morgan TM. Transdermal Penetration 
Enhancers: Applications, Limitations, and 
Potential. J Pharm Sci. 1999; 88(10): 955-958 
7. Aulton ME. Pharmaceutics: The Science of 
Dosage Form Design, 2 nd Edition, 
ChurchillLivingstone. 2002:1-5. 
8. Vyas SP, Khar RK. Controlled Drug Delivery: 
Concepts and Advances. Vallabh Prakashan, 1 st 
Edition, 2002:411-447. 
9. Holmgaard R, Bo Nielsen J, Dermal Absorption 
of Pesticides- Evaluation of variability and 
Prevention, The Danish EnvironmentalProtection 
Agency, Danish 2009;19-24. 
10.  Bucks DA, Maibach HI, Guy RH. Occlusion 
does not uniformly enhance penetration in vivo. 
In: Bronaugh RL,Maibach HI (eds). Percutaneous 
Absorption; Mechanisms, Methodology, Drug 
Delivery, ed 2, New York and Basel, Marcel 
Dekker, 1989:77-93. 
11. Karande P, Mitragotri S. Enhancement of 
transdermal drug delivery via synergistic action 
of chemicals.Biochimica et Biophysica Acta 
2009: 2362-2373. 
12. Porzio S, Caselli G, Pellegrini L, Pallottini V, 
Rosario M, Coppola A, Boltri L, Gentile M. A 
new topical gel-spray formulation of ketoprofen 
lysine salt in the rat: percutaneous permeation in 
vitro and in vivo and pharmacological activity. 
Pharmacol 1998; 37: 41-47. 
13. Babar A, Chickhale PJ, Plakogiannis FM. 
Assessment of triethanolamine salicylate release 
from the dermatological base and the commercial 
products. Pharm Acta Helv 1991; 66: 322. 
14. Bonina FP, Montenegro L. Penetration enhancer 
effects on in vitro percutaneous absorption of 
heparin sodium salt. Int J Pharm 1992; 82: 171. 
15. Hoogstrate AJ, Verhoef J, Brusee, Ijzerman AP, 
Spies F, Bodde HE. Kinetic, ultrastructural 
aspects and molecular modeling of transdermal 
peptide flux enhancement by N-
alkylazocylohepton. Int J Pharm 1991;76: 37-47. 
 Asian Pacific Journal of Health Sciences, 2014; 1(1): 13-25                                        ISSN: 2349-0659                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Kakar et al ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2014; 1(1): 13-25 
www.apjhs.com      24 
 
16. Ogiso T, Iwaki M, Paku T. Effect of various 
enhancers on transdermal penetration of 
indomethacin and urea and relationship between 
penetration parameters and enhancement factors. 
J Pharm Sci 1995; 84: 482. 
17. Ghosh TK, Bagherian A. Development of a 
transdermal patch of methadone: in vitro 
evaluation across hairless mouse and human 
cadaver skin. Pharm Dev Technol 1996; 1: 285. 
18. Karande P, Mitragotri S. Enhancement of 
transdermal drug delivery via synergistic action 
of chemicals. Biochimica et Biophysica Acta 
2009: 2362-2373. 
19. Sinha V, Kaur M. Permeation enhancers for 
transdermal drug delivery. Drug dev and ind 
pharmacy 2000;26(11): 1131-1140. 
20. Karande P, Mitragotri S. Enhancement of 
transdermal drug delivery via synergistic action 
of chemicals. Biochimica et Biophysica Acta 
2009: 2362-2373 
21. Carelli V, Di Colo G. Bile acids as enhancers of 
steroid penetration through excised hairless 
mouse skin. Int J Pharm 1993; 89(2): 81-89. 
22. DV McAllister, PM Wang, SP Davis, et al. 
Prausnitz. Microfabricated needles for 
transdermal delivery of macromolecules and 
nanoparticles: fabrication methods and transport 
studies. Proc. Nat. Acad. Sci. (USA), 2003,100: 
13755-13760. 
23. U. Pliquett, JC Weaver. Electroporation of human 
skin: simultaneous measurement of changes in 
the transport of two fluorescent molecules and in 
the passive electrical properties. Bioelectrochem. 
Bioenerg., 1996, 39: 1-12. 
24. Bromberg L. Cross linked polyethylene glycol 
networks as reservoirs for protein delivery. J. 
Apply. Poly. Sci. 1996; 59:459-66. 
25. Misra, AN, Jain NK, Eds., Controlled and Novel 
Drug Delivery, 1st Edn., CBS Publishers and 
Distributors, New Delhi, 2002, 101-107. 
26. Williams AC, Barry BW. Penetration enhancers, 
Advanced drug delivery reviews. 2004; 56: 603-
18. 
27. Govil SK, In; Tyle, P, Eds., Drug Delivery: 
Fundamentals and Application, Marcel Dekker, 
Inc., New York, 1998, 385-406 
28. Willams AC and barry BW. Penetration 
Enhancers, Adv. Drug Del.Rev.2004;56: 603-618. 
29.  Pellet M, Raghavan SL, Hadgraft J and Davis 
AF. The application of supersaturated systems to 
percutaneous drug delivery. In: Guy R.H and 
Hadgraft J. Transdermal drug delivery, 
MarcelDekker, Inc., New york 2003pp. 305 326. 
30. Brown MB and Jones SA. Hyaluronic acid: 
aunique topical vehicle for localized drug 
delivery of drugs to the skin. JEDV 2000;19:308-
318. 
31. Tsai JC, Guy RH, Thornfeldt CR, GaoWN, 
Feingold K.R and Elias PM. Metabolic 
Approaches to Enchance Transdermal drug 
delivery. Jour.pharm. Sci., 1998; 85:643-648. 
32. Berner B and John VA. Pharmacokinetic 
characterization of Transdermal delivery systems. 
Jour.Clinical pharmacokinetics 1994;26 (2): 121-
34. 
33. Baker W and Heller J. Material Selection for 
Transdermal Delivery Systems, In Transdermal 
Drug Delivery: Developmental Issues and 
Research Initiatives, J.Hadgraft and R.H.Guys, 
Eds. Marcel Dekker, Inc.,New york 1989:. 293-
311. 
34. Wiechers J. Use of chemical penetration 
enhancers in Transdermal drug delivery-
possibilities and difficulties. Acta pharm. 1992: 4: 
123. 
35. Yamamoto T, Katakabe k, Akiyoshi K, Kan K 
and Asano T. Topical application of 
glibenclamide lowers blood glucose levels in rats. 
Diabetes res.Clin. Pract. 1990; 8: 19-22. 
36. Al- Khamis K, Davis SS and Hadgraft J. 
Microviscosity and drug release from topical gel 
formulations. Pharm. Res. 1986; 3: 214-217. 
37. Anon. Transdermal delivery systems-general 
drug release standards. Pharmacopeial Forum, 
1980; 14:3860-3865. 
38. Crawford RR and Esmerian OK. Effect of 
plasticizers on some physical properties of 
cellulose acetate phthalate films. J. Pharm. Sci. 
1997;60: 312-314. 
39. Mayorga P, Puisieux F and Couarraze G. 
Formulation study of a Transdermal delivery 
system of primaquine. Int. J. pharm. 1996; 132: 
71-79. 
40. Deo MR, Sant VP, Parekh SR, Khopade AJ and 
Banakar UV. Proliposome-based Transdermal 
delivery of levonorgestrel. Jour. Biomat. Appl. 
1997; 12: 77- 88. 
41. Singh J, Tripathi KT and Sakia TR. Effect of 
penetration enhancers on the invitro transport of 
ephedrine through rate skin and human epidermis 
from matrix based Transdermal formulations. 
Drug Dev. Ind. Pharm. 1993; 19: 1623-1628.  
42. Wade A, Weller PJ. Handbook of pharmaceutical 
Excipients. Washington, DC: American 
Pharmaceutical Publishing Association; 1994: 
362-366.  
 Asian Pacific Journal of Health Sciences, 2014; 1(1): 13-25                                        ISSN: 2349-0659                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Kakar et al ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2014; 1(1): 13-25 
www.apjhs.com      25 
 
43. Sharma Tejal, Rawal Gaurav.Transdermal 
Therapeutic Systems: An Overview. 
International Journal of Pharmaceutical & 
Biological Archives 2011; 2(6):1581-1587. 
44. Shaila L, Pandey S and Udupa N. Design and 
evaluation of matrix type membrane controlled 
Transdermal drug delivery system of nicotin 
suitable for use in smoking cessation. Indian 
Journ. Pharm. Sci. 2006;68: 179-184. 
45. Aarti N, Louk ARMP, Russsel OP and Richard 
HG. Mechanism of oleic acid induced skin 
permeation enhancement in vivo in humans. Jour. 
control. Release 1995; 37: 299-306.  
46. Wade A and Weller PJ. Handbook of 
pharmaceutical Recipients. Washington, DC: 
American Pharmaceutical Publishing Association 
1994; 362-366.  
47. Lec ST, Yac SH, Kim SW and Berner B. One 
way membrane for Transdermal drug delivery 
systems / system optimization. Int. J Pharm. 
1991; 77: 231 -237. 
48. MF Coldman, BJ Poulsen, T Higuchi. 
Enhancement of percutaneous absorption by the 
use of volatile: nonvolatile systems as vehicles. J. 
Pharm. Sci., 1969, 58: 1098-1102. 
49. K Moser, K Kriwet, YN Kalia. Enhanced skin 
permeation of a lipophilic drug using 
supersaturated formulations. J. Control. Release, 
2001; 73: 245-253. 
50. AF Davis, J Hadgraft. Effect of supersaturation 
on membrane transport. Hydrocortisone acetate. 
Int. J. Pharm.,1991; 76: 1-8. 
51. K Moser, K Kriwet, C Froehlich, et al. 
Permeation enhancement of a highly lipophilic 
drug using supersaturated systems. J. Pharm. 
Sci., 2001;90: 605-614. 
52. S Kondo, D Yamanaka, ISugimoto. Enhancement 
of transdermal delivery by superfluous 
thermodynamic potential. III. Percutaneous 
absorption of nifedipine in rats.J. Pharmacobio-
Dyn., 1987;10: 743-749. 
53. S Lee, N Kollias, DJ McAuliffe. Topical drug 
delivery in humans with a single 
photomechanical wave. Pharm. Res., 1999;16: 
1717-1721. 
54. GK Menon, PM Elias. Morphologic basis for a 
porepathway in mammalian stratum corneum. 
Skin Pharmacol.,1997;10: 235-246. 
55. S Lee, DJ McAuliffe, SE. Mulholland. 
Photomechanical transdermal delivery of insulin 
in vivo.Lasers Surg. Med., 2001;28: 282-285. 
56. M Terakawa, H Tsuda, H. Ashida. Assessment of 
tissue alteration in skin after interaction with 
photomechanical waves used for gene 
transfection. Lasers Surg Med., 2010;42: 400-
407. 
57. VP Shah, CC Peck, RL Williams, in: Walters 
KA, Hadgraft J (Eds.), pharmaceutical skin 
penetration enhancement, Marcel Dekker, New 
York, 1993, 417-427. 
58.  AC Williams, BW Barry. Penetration enhancers. 
Adv.Drug Del. Rev., 2004, 56: 603-618. 
59. JY Fang, CF Hung, YP. Fang. Transdermal 
Iontophoresis of 5-fluorouracll combined with 
Electroporation and laser treatment. Int. J. 
Pharm., 2004;270:241-249. 
60. Tam Emily, Furkan Andrea D. Transdermal 
Lidocaine and Ketamine for Neuropathic Pain: A 
Study of Effectiveness and Tolerability.Open 
Neurol J. 2012; 6: 58–64. 
61. Schwarz Pharma’s Neupro (rotigotine 
Transdermal Patch) Offers Additional Benefits 
For Parkinson’s Disease.” Medical News Today, 
Sep 6, 2006: http://www.medicalnewstoday. 
com/healthnews.php?newsid=51282 (December 
18, 2006). 
62. Bülow HH, Linnemann M, Berg H, Lang-Jensen 
T, LaCour S, Jonsson T . "Respiratory changes 
during treatment of postoperative pain with high 
dose transdermal fentanyl". Acta Anaesthesiol 
Scand .1995;39 (6): 835–9. 
63. Rose JE,  Herskovic JE,  Trilling Y, Jarvik ME. 
Transdermal nicotine reduces cigarette craving 
and nicotine preference. Clinical pharmacology 
and therapeutics.1985; 38 (4): 450–456. 
64. Burner B, John VA. Pharmacokinetic 
characterisation of transdermal drug delivery 
system.Clinicalpharmacokinetics.1994;26(2):121
-134 
 
Source of Support: NIL 
Conflict of Interest: None 
 
